Search
Tolazoline
go.drugbank.com/drugs/DB00797ApprovedVet approvedWithdrawnA vasodilator that apparently has direct actions on blood vessels and also increases cardiac output.
Tridihexethyl
go.drugbank.com/drugs/DB00505ApprovedWithdrawnTridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key … [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian
Cetylpyridinium
go.drugbank.com/drugs/DB11073ApprovedInvestigationalIts salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays.
Oxilofrine
go.drugbank.com/drugs/DB11610ApprovedOxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.
Vasopressin
go.drugbank.com/drugs/DB00067ApprovedInvestigational[A228013] It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.[L31413] … [A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951.
Technetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawnIt was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.
Camostat
go.drugbank.com/drugs/DB13729Investigational[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198771,A198777,A193800] Camostat mesylate was first approved in Japan in January 2006.[L13197]
Ramelteon
go.drugbank.com/drugs/DB00980ApprovedInvestigationalRamelteon has not been shown to produce dependence and has shown no potential for abuse.
Proxibarbal
go.drugbank.com/drugs/DB13253ApprovedProxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476]. … Proxibarbal is a derivative of barbiturates, which has been used to treat migraines.